Free Trial

Centene (CNC) Stock Forecast & Price Target

Centene logo
$59.90 +0.64 (+1.08%)
As of 03:59 PM Eastern

Centene - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
7
Buy
9

Based on 16 Wall Street analysts who have issued ratings for Centene in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 7 have given a hold rating, and 9 have given a buy rating for CNC.

Consensus Price Target

$79.77
33.17% Upside
According to the 16 analysts' twelve-month price targets for Centene, the average price target is $79.77. The highest price target for CNC is $90.00, while the lowest price target for CNC is $61.00. The average price target represents a forecasted upside of 33.17% from the current price of $59.90.
Get the Latest News and Ratings for CNC and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Centene and its competitors.

Sign Up

CNC Analyst Ratings Over Time

TypeCurrent Forecast
4/30/24 to 4/30/25
1 Month Ago
3/31/24 to 3/31/25
3 Months Ago
1/31/24 to 1/30/25
1 Year Ago
5/1/23 to 4/30/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
6 Buy rating(s)
Hold
7 Hold rating(s)
5 Hold rating(s)
4 Hold rating(s)
6 Hold rating(s)
Sell
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$79.77$79.92$80.92$85.00
Forecasted Upside33.17% Upside31.51% Upside25.20% Upside16.34% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

CNC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CNC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Centene Stock vs. The Competition

TypeCenteneMedical CompaniesS&P 500
Consensus Rating Score
2.56
2.82
2.54
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside34.52% Upside3,078.58% Upside20.06% Upside
News Sentiment Rating
Positive News

See Recent CNC News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/29/2025Jefferies Financial Group
2 of 5 stars
David Windley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetHold ➝ Hold$64.00 ➝ $61.00+2.98%
4/29/2025Guggenheim
2 of 5 stars
J. Cassorla
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
4/28/2025Barclays
3 of 5 stars
Andrew Mok
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$93.00 ➝ $84.00+41.88%
4/15/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Michael Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$71.00 ➝ $69.00+9.63%
2/14/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Stephen Baxter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$76.00 ➝ $72.00+26.47%
2/6/2025Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Staszak
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
12/17/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Overweight$80.00 ➝ $75.00+26.75%
12/13/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$75.00 ➝ $73.00+22.09%
12/13/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$89.00 ➝ $84.00+42.45%
12/13/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$95.00 ➝ $85.00+46.55%
12/13/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Caliendo
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$79.00 ➝ $80.00+37.93%
12/11/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$90.00 ➝ $90.00+63.07%
10/30/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$96.00 ➝ $88.00+42.19%
8/2/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$82.00 ➝ $87.00+11.80%
7/31/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$80.00 ➝ $89.00+14.68%
5/30/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
9/5/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Neutral$79.00 ➝ $72.00+17.51%
8/30/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight$94.00 ➝ $73.00+13.28%
7/12/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Peer Perform
7/11/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$80.00 ➝ $76.00+12.91%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 05:53 PM ET.


Should I Buy Centene Stock? CNC Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 23, 2025. Please send any questions or comments about these Centene pros and cons to contact@marketbeat.com.

Centene
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Centene Co.:

  • The current stock price is around $58, which may present a buying opportunity for investors looking for value in the healthcare sector.
  • Centene Co. reported strong quarterly earnings, with earnings per share significantly exceeding analyst expectations, indicating robust financial performance.
  • The company has shown a year-over-year revenue increase of 3.4%, suggesting growth potential and resilience in its business model.
  • Analysts have a consensus rating of "Moderate Buy" for Centene Co., with a favorable average price target, indicating positive market sentiment.
  • Centene Co. operates in multiple segments, including Medicaid and Medicare, which diversifies its revenue streams and reduces dependency on any single market.

Centene
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Centene Co. for these reasons:

  • Despite recent earnings growth, the company's net margin is relatively low, which may indicate challenges in maintaining profitability.
  • Centene Co. has received mixed ratings from analysts, with some downgrading their price targets, reflecting uncertainty about future performance.
  • The stock has a beta of 0.53, suggesting lower volatility compared to the market, which may limit potential high returns for aggressive investors.
  • With a debt-to-equity ratio of 0.70, the company carries a moderate level of debt, which could pose risks if market conditions change.
  • Recent market trends in the healthcare sector may lead to increased competition, potentially impacting Centene Co.'s market share and growth prospects.

CNC Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Centene is $79.77, with a high forecast of $90.00 and a low forecast of $61.00.

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Centene in the last twelve months. There are currently 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CNC shares.

According to analysts, Centene's stock has a predicted upside of 33.17% based on their 12-month stock forecasts.

Over the previous 90 days, Centene's stock had 1 upgrade and 1 downgrade by analysts.

Centene has been rated by research analysts at Argus, Barclays, Guggenheim, Jefferies Financial Group, Robert W. Baird, and Wells Fargo & Company in the past 90 days.

Analysts like Centene less than other "medical" companies. The consensus rating score for Centene is 2.56 while the average consensus rating score for "medical" companies is 2.82. Learn more on how CNC compares to other companies.


This page (NYSE:CNC) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners